a
Based on the additional slides you've shared, Professor Turner is moving from the "rules" of the 2025 guidelines into the "Art of Medicine"—the messy reality where clinical data doesn't always provide a clear "yes" or "no."
Here is an elaboration on how these specific cases (Chloe vs. Muhammad) illustrate the new UK asthma standards.
1. Chloe: The "Textbook" Diagnosis
Chloe’s slide represents a high probability of asthma. Under the new guidelines, she is the ideal candidate for a quick and confident diagnosis.
Positive Indicators: She has the "atopic triad" (asthma symptoms, eczema, and a positive skin prick test).
The "Rule In" Test: Her FeNO is 38 ppb. In the 2025 Joint Guideline, any child with symptoms and a FeNO $\ge$ 35 ppb is a confirmed case.
The Spirometry Paradox: Note that her $FEV_1$ is 98% (normal). Professor Turner uses this to show that normal lung function does not rule out asthma, especially when the child is not currently having a "flare."
2. Muhammad: The Diagnostic Dilemma
Muhammad is the "real world" case where the 2025 guidelines require more legwork.
The Conflict: He has the symptoms (cough, wheeze, DIB), but his FeNO is 28 ppb.
The "Intermediate" Zone: For children, 20–34 ppb is the "grey area." You cannot diagnose him on FeNO alone.
The Strategy: As we discussed, Muhammad would now require a second objective test (like Peak Flow monitoring) or a coded "Trial of Treatment" to see if he responds to a low-dose preventer.
3. "Welcome to the Art of Medicine!"
The final slide you uploaded is the "clinician’s reality check." It highlights why asthma remains one of the hardest conditions to manage perfectly:
No Definition/Definitive Test: There is no single blood test or X-ray that "is" asthma. It is a syndrome of symptoms.
The Triple Threat: Diagnosis relies on the presence of Cough AND Wheeze AND DIB (Difficulty in Breathing). If a child only has a cough, the 2025 guidelines suggest looking for other causes (like reflux or "habit cough") before labeling it asthma.
Response to Steroids: A "history of responding to steroids" remains one of the strongest clinical indicators, even if the breathing tests are borderline.
Summary of the 2025 Clinical Shift
| Feature | Old Approach (Pre-2024) | New Approach (Current 2026) |
| First Step | Clinical suspicion + trial of "Blue Inhaler" | Objective Test First (FeNO) |
| Confirmation | Subjective (does the patient feel better?) | Objective (FeNO $\ge$ 35 or PEF variability $\ge$ 20%) |
| Labeling | Diagnosed quickly | Use "Suspected Asthma" code for intermediate cases |
Key Terminology from the Slides:
SABA: Short-Acting Beta-Agonist (the Blue "Reliever" inhaler).
FeNO: Fractional Exhaled Nitric Oxide (measures allergic inflammation).
$FEV_1$: Forced Expiratory Volume in 1 second (measures how much air you can blow out fast).
FHx: Family History (crucial for Chloe, absent for Muhammad).
Would you like me to detail the specific "Trial of Treatment" protocol Professor Turner recommends for "Intermediate" cases like Muhammad?
a
The final slide in Professor Turner's set brings us to the Step-wise Pharmacological Management for children aged 5–16. This is where the 2025 Joint Guideline makes its most significant departure from previous years by prioritizing Anti-Inflammatory Reliever (AIR) and MART therapies.
The goal is to move away from "SABA-only" (blue inhaler) treatment, which is now recognized as a major risk factor for life-threatening attacks.
The New Pediatric Treatment Steps (Aged 5–16)
The guideline emphasizes that every child's treatment should be personalized, but follows this general "ladder":
| Step | Clinical Status | Recommended Therapy |
| Step 1 | Infrequent symptoms | Paediatric Low-dose ICS (Preventer) taken daily + SABA (Reliever) as needed. |
| Step 2 | Uncontrolled on Step 1 | Paediatric Low-dose MART: A single inhaler (e.g., Symbicort 100/6) used for both daily maintenance and as a reliever. |
| Step 3 | Uncontrolled on Step 2 | Paediatric Moderate-dose MART: Increase the daily maintenance dose of the MART inhaler. |
| Step 4 | Persistent symptoms | Add-on Therapy & Referral: Consider adding an LTRA (Montelukast) and refer to a specialist respiratory pediatrician. |
Why the Shift to MART?
Professor Turner highlights that MART (Maintenance and Reliever Therapy) is a "game-changer" for children because:
Automatic Anti-inflammatory: Every time a child reaches for their inhaler because they are wheezy, they get a small dose of steroid to treat the underlying swelling, not just the "squeeze."
Simplicity: It removes the confusion of having two different colored inhalers (the "Which one do I use now?" problem).
Licensed Update: As noted in the November 2025 update, specific dry powder inhalers (100mcg/6mcg) are now officially licensed for MART in children as young as 6 years old.
Professor Turner’s "Golden Rules" for 2026
To wrap up the presentation, Turner likely emphasizes these three pillars for any clinician managing a child like Chloe or Muhammad:
Objective Testing is Mandatory: Do not diagnose on a "hunch." Use FeNO and Spirometry.
The "Suspected Asthma" Safety Net: If tests are intermediate, use the "Suspected Asthma" code and review in 3 months rather than giving a permanent diagnosis.
Kill the "Blue Inhaler" Reliance: If a child is using $\ge$ 3 SABA canisters a year, their treatment must be escalated. This is a red flag for a future severe attack.
Summary of Diagnostic Thresholds (Quick Reference)
Confirm Asthma: FeNO $\ge$ 35 ppb OR BDR $\ge$ 12% OR PEF variability $\ge$ 20%.
Suspect Asthma: FeNO 20–34 ppb (the "Muhammad" zone) requires further testing or a trial of treatment.
Would you like me to summarize the "Green Asthma" section of the guidelines, which explains why we are switching children from sprays (MDIs) to dry powder inhalers (DPIs)?
No comments:
Post a Comment